

investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on June 24, 2016, based on a complaint filed by Intex Recreation Corp. of Long Beach, California; and Intex Marketing Ltd. of Tortola, British Virgin Islands (together, “Intex”). 81 FR 41346–47. The complaint alleges that respondents Bestway (USA), Inc., of Phoenix, Arizona; Bestway Global Holdings, Inc. of Shanghai, China; Bestway (Hong Kong) International Ltd. of Hong Kong; Bestway Inflatables & Materials Corporation of Shanghai, China; and Bestway (Nantong) Recreation Corp. of Nantong, China (together, “Bestway”), are in violation of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, by reason of infringement of certain claims of U.S. Patent Nos. 8,562,773 and 9,156,203. *Id.* The Office of Unfair Import Investigations (“OUII”) is a party to the investigation. *Id.* at 41347.

On July 14, 2016, Bestway filed a motion to terminate the investigation based upon a consent order stipulation and proposed consent order. That same day, OUII filed a response arguing that the motion should be granted because it complies with the Commission Rules for consent orders and termination serves the public interest. Intex did not respond to the motion.

On July 25, 2016, the ALJ granted the motion in the subject ID. She found that the motion for termination by consent order stipulation complies with the requirements of Commission Rule 210.21(c) and is in the public interest. No petitions for review of the ID were received.

The Commission has determined not to review the subject ID and to issue a consent order. The investigation is terminated in its entirety.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part

210 of the Commission’s Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.  
Issued: August 18, 2016.

**Lisa R. Barton,**

*Secretary to the Commission.*

[FR Doc. 2016–20200 Filed 8–23–16; 8:45 am]

**BILLING CODE 7020–02–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–392]

**Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 24, 2016.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:**

The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been re-delegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on July 27, 2016, Chattem Chemicals, 3801 St. Elmo Avenue, Chattanooga, Tennessee 37409 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Schedule
Gamma Hydroxybutyric Acid (2010).	I
4-Methoxyamphetamine (7411) ...	I

Controlled substance	Schedule
Dihydromorphine (9145) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Lisdexamfetamine (1205) .....	II
Methylphenidate (1724) .....	II
Pentobarbital (2270) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Hydrocodone (9193) .....	II
Meperidine (9230) .....	II
Meperidine intermediate–A (9232)	II
Meperidine intermediate–B (9233)	II
Meperidine intermediate–C (9234)	II
Methadone (9250) .....	II
Methadone intermediate (9254) ...	II
Morphine (9300) .....	II
Oripavine (9330) .....	II
Thebaine (9333) .....	II
Opium tincture (9630) .....	II
Opium, powdered (9639) .....	II
Opium, granulated (9640) .....	II
Oxymorphone (9652) .....	II
Noroxymorphone (9668) .....	II
Alfentanil (9737) .....	II
Remifentanil (9739) .....	II
Sufentanil (9740) .....	II
Tapentadol (9780) .....	II
Fentanyl (9801) .....	II

The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers.

**Louis J. Milione,**

*Deputy Assistant Administrator.*

[FR Doc. 2016–20241 Filed 8–23–16; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–392]

**Importer of Controlled Substances Application: Noramco, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before September 23, 2016. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before September 23, 2016.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement